INT27409

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.46
First Reported 1980
Last Reported 2008
Negated 0
Speculated 0
Reported most in Abstract
Documents 6
Total Number 6
Disease Relevance 2.06
Pain Relevance 1.13

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Ptgfr) plasma membrane (Ptgfr) signal transducer activity (Ptgfr)
Anatomy Link Frequency
platelets 2
PGE2 2
Ptgfr (Mus musculus)
Pain Link Frequency Relevance Heat
Pain 4 95.80 Very High Very High Very High
diclofenac 2 93.64 High High
aspirin 9 92.56 High High
cINOD 5 88.60 High High
Inflammation 5 77.92 Quite High
antagonist 51 69.52 Quite High
agonist 2 61.56 Quite High
withdrawal 2 5.00 Very Low Very Low Very Low
cerebral cortex 1 5.00 Very Low Very Low Very Low
adenocard 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disease 2 98.36 Very High Very High Very High
Arthritis 1 98.04 Very High Very High Very High
Pain 4 95.80 Very High Very High Very High
Tinnitus 2 92.72 High High
Dizziness 2 91.92 High High
Natriuresis 2 90.80 High High
Gastritis 2 90.80 High High
Adenocarcinoma 9 88.64 High High
INFLAMMATION 8 88.04 High High
Cancer 7 85.84 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
On the other hand, PGF2 alpha increases the synthesis of PGE2 and 6-keto PGF1 alpha while 6-keto PGF1 alpha solely inhibits PGF2 alpha release, PGE2 being inactive.
Negative_regulation (inhibits) of Localization (release) of PGF2
1) Confidence 0.46 Published 1989 Journal Prostaglandins Leukot. Essent. Fatty Acids Section Abstract Doc Link 2608699 Disease Relevance 0.31 Pain Relevance 0.33
Moreover, we believe that these data have implications for the use of prostaglandin synthase inhibitors targeted against PGF synthase as therapeutic intervention strategies as suggested for PGE synthase (Murakami and Kudo, 2006; Jachak, 2007; Wang et al., 2006; Cheng et al., 2006).
Negative_regulation (inhibitors) of Localization (targeted) of PGF synthase
2) Confidence 0.03 Published 2008 Journal Molecular and Cellular Endocrinology Section Body Doc Link PMC2694994 Disease Relevance 0.17 Pain Relevance 0.03
The mean urinary PGE2 and PGF2 excretion was reduced by 35-63% and 63-85%, respectively.
Negative_regulation (reduced) of Localization (excretion) of PGF2 in PGE2
3) Confidence 0.02 Published 1980 Journal Acta Pharmacol Toxicol (Copenh) Section Abstract Doc Link 7361561 Disease Relevance 0.24 Pain Relevance 0.28
Thus the suppression of PGF2 alpha release does not reflect the therapeutic response of these drugs.
Negative_regulation (suppression) of Localization (release) of PGF2
4) Confidence 0.01 Published 1981 Journal Scand. J. Rheumatol. Section Abstract Doc Link 7017917 Disease Relevance 0.54 Pain Relevance 0.22
Both ASA doses induced complete inhibition of prostaglandin PGF2 alpha release from platelets.
Negative_regulation (inhibition) of Localization (release) of PGF2 in platelets
5) Confidence 0.01 Published 1981 Journal Scand. J. Rheumatol. Section Abstract Doc Link 7017917 Disease Relevance 0.53 Pain Relevance 0.22
Indomethacin decreased the urinary excretion of PGF2 alpha by about 70% and 6-keto-PGF1 alpha and thromboxane (Tx)B2, the stable break-down products of prostacyclin and TxA2 respectively, by about 40%.
Negative_regulation (decreased) of Localization (excretion) of PGF2
6) Confidence 0.00 Published 1989 Journal Prostaglandins Leukot. Essent. Fatty Acids Section Abstract Doc Link 2616586 Disease Relevance 0.27 Pain Relevance 0.05

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox